Navigation Links
The next era in discovering drugs in nature's own medicine cabinet
Date:9/4/2013

New technology for discovering antibiotics, anti-cancer drugs and other medicines inside soil microbes and other natural sources is reviving a treasure hunt that already has given humanity more than 50 percent of today's prescription drugs. This new era in "bioprospecting" is the topic of the cover story in Chemical & Engineering News, the weekly newsmagazine of the American Chemical Society.

Lisa M. Jarvis, C&EN senior editor, points out that natural products are the source of about half of the modern drugs approved in the U.S. But the search for new products slowed as drug companies learned to make synthetic compounds at high speeds by the thousands. Now, the increasing availability and affordability of DNA sequencing is reviving activity in the field. It enables scientists to sample the DNA of thousands of microbes at once in search of gene clusters that could yield a new drug. Then computer models can figure out what molecules the genes encode, and organize the information in searchable databases.

The potential for discovering new medicines is high enough to attract the attention and millions of dollars in investments of some of the pharmaceutical industry's major players, including Sanofi and Novartis. The article notes that the latest research has significantly increased the number of microbial compounds being discovered and has opened a window on a vast new library of genes and gene clusters that code for previously undiscovered drugs. The flood of genetic discovery underpins expectations that potential new medicines based on natural products will be in clinical trials in humans within a few years.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers develop tools for discovering new species
2. Discovering cell surface proteins behavior
3. Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
4. First update in a century in testing drugs for elemental impurities
5. New drugs to find the right target to fight Alzheimers disease
6. Alternative target for breast cancer drugs
7. Toward broad-spectrum antiviral drugs for common cold and other infections
8. Gene variants may predict who will benefit from breast cancer prevention drugs
9. New screening technique paves the way for protein drugs from bacteria
10. Soda and illegal drugs cause similar damage to teeth
11. A new strategy required in the search for Alzheimers drugs?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... announces that it has just released a new white paper authored by Zettar that ... speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) ... portfolio of bioprocess media products engineered to radically streamline culture processes, minimize ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... ... 2016 , ... ACEA Biosciences, Inc. presented today updated efficacy ... for its lead drug candidate, AC0010, at the World Conference on Lung Cancer ... the safety, antitumor activity, and recommended phase II dosage of AC0010 in T790M-postitive ...
(Date:12/7/2016)... Capital Corp. ("Zenith" or the "Company") announces webcast details for ... Annual and Special Meeting. The Zenith Annual ... December 15, 2016 at Mount Royal ... Royal Gate SW, Calgary, Alberta , commencing ... information circular, containing the matters to be considered at the ...
Breaking Biology Technology: